Marksans Pharma Limited · NSE:MARKSANS
Marksans Pharma — Investor Presentation (October 2014)
21 slides from Marksans Pharma's investor presentation, October 2014
Slide 1: Marksans Pharma Limited Corporate Presentation October 2014
Marksans Pharma Limited Corporate Presentation October 2014
Slide 2: An Overview
Marksans Pharma Ltd. Health Care in Safe Hands An Overview
Slide 3: Business Overview
Business Overview Background Revenue Split by Therapeutic Segment Marksans Pharma Limited (“Marksans” or “the Company”) promoted by Mr. Mark Saldanha is manufacturer of generic pharmaceuticals across regulated markets – Therapeutic Segments FY14 (in INR mn) In % soft gelatin capsules & tablets in
Slide 4: Corporate Structure & Key Business Verticals
Corporate Structure & Key Business Verticals India − Facility in Goa, India to manufacture oral solid dosages & soft gelatin Marksans Pharma capsules Limited − USFDA, UKMHRA and TGA accredited UK 100% Australia 60% Marksans Pharma Nova Pharmaceuticals (UK) Limited Australasia Pty. Ltd. − Distributio
Slide 5: History & Evolution of the Company
History & Evolution of the Company 5
Slide 6: The Company has had 4 Phases thus far in its Evolution
The Company has had 4 Phases thus far in its Evolution… History – Early Days (FY04-06) Marksans is a result of a merger between Glenmark Laboratories Ltd. and TASC Pharma in March 2005 and hence became publicly listed on the NSE & BSE Subsequently, it changed its name to Marksans Pharma Limited
Slide 7: Margins & growth have rebounded; balance sheet deleveraged
…with a visible improvement seen in the last 2 years An earlier stretched balance sheet is now deleveraged Margins & growth have rebounded in recent times… with Debt/Equity dropping from a high of 2.5x to ..translating into improved interest coverage 0.6x 55 3.0 14.0 11.1 40 11.2 2.4 2.4 25 2.5 8.4
Slide 8: Key Highlights
Marksans Pharma Ltd. Health Care in Safe Hands Key Highlights
Slide 9: Key Highlights
Key Highlights Manufacturing facilities with global major regulatory accreditations Well poised to capture the niche softgel opportunity Expanding presence in the US market to be a key focus area Targeting existing global markets for growth Focused & experienced senior management team 9
Slide 10: Manufacturing facilities with global major regulatory accreditations
Manufacturing facilities with global major regulatory accreditations Goa Plant – Capsules & Tablets Southport, UK Plant – Liquids, Ointments & Powders Facility for manufacturing soft gelatin capsules & tablets Primarily used to produce formulations (non-sterile liquids, ointments & powder produc
Slide 11: Well poised to capture the niche softgel opportunity
Well poised to capture the niche softgel opportunity Advantages of Softgels Manufacturing Softgels entails a complex series of steps Easy to swallow & readily dissolves Masks odour and unpleasant tastes Enhances bioavailability of the active ingredient Higher shelf life than the traditional
Slide 12: Growth in formulations business is supported by a high margin & cash generating CRAMS vertical
Growth in formulations business is supported by a high margin & cash generating CRAMS vertical CRAMS: Leveraging R&D and manufacturing capabilities The CRAMS business broadly comprises: – External CRAMS: Global pharmaceutical companies like Sandoz, Teva and Actavis – Subsidiary CRAMS: MRKS’ subsid
Slide 13: Focused & experienced senior management team
Focused & experienced senior management team Marksans Pharma is led by the dynamic leadership of Mr. Mark Saldanha... Mr. Saldanha is the founder promoter of the company He is also the Chairman & Managing Director of Marksans Mr. Mark Saldanha A science graduate with more than two decades of e
Slide 14: Business Strategy
Marksans Pharma Ltd. Health Care in Safe Hands Business Strategy eee
Slide 15: Business Strategy
Business Strategy Focus on increasing sales from existing approved ANDAs (e.g., scale up contracts with branded retail players for Ibuprofen Expanding the US softgel) business through To be the first to file the product in the US aiming for Day 1 launch after patent expiry filings and tie-ups
Slide 16: Appendix
Marksans Pharma Ltd. Health Care in Safe Hands Appendix 16
Slide 17: Financial Overview (1/2)
Financial Overview (1/2) Income statement (INR mn) Particulars FY14 (Consolidated) FY13 (Consolidated) Sales 6,300.0 4,384.2 Other Income 35.0 44.0 Total Income 6,335.0 4,428.2 Cost of materials consumed 2,290.5 1,359.3 Purchases of Stock-in-Trade 1,416.5 1,047.8 Changes in inventories of finished g
Slide 18: Financial Overview (2/2)
Financial Overview (2/2) Balance sheet (INR mn) Particulars FY 14 (Consolidated) FY 13 (Consolidated) Equity & Liabilities Share Capital 520.30 520.31 Reserves and surplus 901.50 344.48 Minority Interest 66.40 69.90 Share Application money pending allotment Total Equity 1,488.20 934.69 Non-current l
Slide 19: Product Portfolio (1/2)
Product Portfolio (1/2) USA Products ROW Products 19
Slide 20: Product Portfolio (2/2)
Product Portfolio (2/2) Bell’s OTC Products Nova Australia Products 20
Slide 21: Disclaimer
Disclaimer The information in this presentation has been prepared by Marksans Pharma Limited (the “Company”) and has not been independently verified. No representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correct
Marksans Pharma — Investor Presentation (October 2014) on 6ix